## **Ublituximab-xiiy (Briumvi)**

Provider Order Form rev. 01/02/2024

PATIENT IN	IFORMATION	Referral Stat	t <b>us:</b> □ New R	eferral 🔲 Updated (	Order □ Order Renewal
Patient Nam	e:		DOB:	Patient F	Phone:
Patient Address:			Patient Email:		
Allergies:			□ NKDA	Weight (lbs/kg):	Height (in/cm):
Sex: ☐ M / ☐ F Date of Last Infusion: Next Due		Date:	Preferred Location		
DIAGNOSI	S (Please provide ICD-10	code in space provided)			
Multiple Scle		, ,			
Other:	Descri	otion:			
THERAPY ADMINISTRATION  ☐ Induction Week 0: Administer Briumvi 150mg diluted in 250ml NS and infused over 4 hours (infusion rates below) ☐ Induction Week 2 & week 24: Administer Briumvi 450mg diluted in 250ml NS and infused over 1 hour (infusion rates below) ☐ Maintenance: Administer Briumvi 450mg every 6months (24weeks) diluted in 250ml NS and infused over 1 hour ☑ Monitor Patient for 60mins after the first 2 infusions			PRE-MEDICATION ORDERS  ☑ All pre-medication needs to be administered 30 minutes prior to infusion ☐ Tylenol ☐ 500mg / ☐ 650mg PO ☐ Loratadine 10mg PO ☐ Pepcid 20mg ☐ PO / ☐ IVP ☐ Benadryl ☐ 25mg / ☐ 50mg ☐ PO / ☐ IVP ☐ Solumedrol ☐ 40mg / ☐ 125mg IVP ☐ Other:		
DOSING R	EFERENCE		□ Other:		
Infusion 150mg dose (Duration at least 4 hours) 450mg dose (Duration at least 1 hour)  0 10 ml/hr x30mins 100ml/hr x 30mins 30 min 20 ml/hr x30mins 400ml/hr x 30mins 60 min 35ml/hr x60mins 120 min 100 ml/hr x120mins  ADDITIONAL ORDERS			NURSING  ☑ Hold infusion and notify provider for:  • Signs/symptoms of infection  • Recent live vaccines  • POSITIVE pregnancy test  ☑ Monitor vital signs with every rate change, then every 60 minutes and prior to discharge  ☑ Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-procedure observation		
PROVIDER Preferred Co Ordering Pro				ferred Contact Email: vider NPI:	
	Referring Practice Name:		Phone:	Phone: Fax:	
	Practice Address:		City:	State:	Zip Code:
Required Do treatment fa	cumentation: Patient der ilures or contraindication	CHECKLIST (Additional dock mos, copy of front and back of s, MRI results Quantitative Immunoglobulin	of primary and	secondary insurance, 2	most recent OVN including
Provider Na	rovider Name (print) Provider Signat		ure		Date